A steroid dose can wake up a worm that's been quietly cycling in a patient's gut for forty years. This is the fact-check and full work-up behind the "evidence-based ivermectin" carousel — mechanism, who to screen, why stool testing fails, and the empiric-treatment argument on both sides.
Every other intestinal helminth needs to leave the host and come back. This one doesn't.
Strongyloides stercoralis is a soil-transmitted nematode that infects roughly 600 million people worldwide, mostly in the tropics and subtropics — but also in pockets of the historically endemic American South and Appalachia, where autochthonous (locally acquired) transmission has been documented for over a century.primary source checked
Free-living filariform larvae penetrate intact skin (classically bare feet on contaminated soil), migrate through the bloodstream to the lungs, are coughed up and swallowed, and mature into adult females in the small intestine. So far, this looks like any other soil-transmitted helminth.
The difference: some larvae produced in the gut molt into the infective filariform stage before they're passed in stool. Instead of leaving the host, they re-penetrate the intestinal mucosa or perianal skin and re-enter circulation — restarting the cycle entirely inside the same person. This is why Strongyloides can persist for decades after the last soil exposure, often with no symptoms beyond intermittent GI upset, a recurring pruritic serpiginous rash (larva currens), or unexplained eosinophilia.
Corticosteroids don't cause the infection — they remove the ceiling on it.
Chronic autoinfection stays low-grade because host immunity (particularly eosinophils, IgE, and Th2-mediated responses) keeps the larval cycling in check. Corticosteroids blunt exactly that arm of immunity. The mechanism proposed in the literature is not purely immunologic: glucocorticoids also appear to act directly on the parasite, accelerating the molt from the rhabditiform to the infective filariform larval stage — effectively giving the worm a hormonal green light to accelerate its own life cycle independent of the immune suppression.primary source checked
Once that ceiling is gone, hyperinfection syndrome follows: larval burden increases by orders of magnitude, migration extends beyond the normal gut-lung circuit into the CNS, liver, and elsewhere (frank dissemination), and the migrating larvae drag enteric gram-negative organisms across a mechanically disrupted gut wall into the bloodstream — meaning the fatal event is often gram-negative sepsis or meningitis, not the parasite itself.
On the numbers: the original carousel's "up to 60%+" is a defensible conservative floor. Case-series data more commonly cite 70–100% mortality for frank dissemination, and ~90% for untreated hyperinfection broadly — both figures independently corroborated across a 2022 neurosurgical case report, a 2023 obstetric case report, and a 2022 review in Lung. One recent systematic review of hyperinfection with thrombotic complications specifically found 31.3% mortality — lower, but drawn from a narrower and more heavily treated cohort, not evidence the disease is generally survivable without recognition.primary source checked
The carousel's hint was right: geography of birth is only one risk flag among several.
Guidance-level consensus (IDSA-aligned transplant guidelines, ASBMT, World Gastroenterology Organisation) recommends screening before any planned immunosuppression — transplant candidacy, prolonged corticosteroids, biologics, chemotherapy — in anyone with a plausible exposure history.primary source checked That history is broader than "born or lived abroad":
| Risk group | Why they're missed |
|---|---|
| Residents of the historically endemic Southeastern U.S. and Appalachia | Domestic transmission is under-recognized; a 2025 South Carolina serosurvey found 5.0% seropositivity in banked serum, and a Kentucky transplant-center cohort found 9.5% seropositive among evaluees, highest among rural Appalachian residents (14%+) |
| Military veterans, especially Vietnam/SE Asia-era service | Exposure decades in the past; the autoinfection cycle means the worm outlives the memory of the exposure |
| Immigrants/refugees from endemic regions, regardless of years in the U.S. | Chronic asymptomatic carriage; screening at entry historically inconsistent outside formal refugee resettlement pathways |
| Anyone with unexplained peripheral eosinophilia | Eosinophilia is a clue, not a rule-out — it is frequently absent, especially once immunosuppression has already begun |
Practically: any patient about to receive prolonged corticosteroids, biologic immunosuppression, or transplant conditioning who has any plausible soil exposure history — domestic or international, recent or decades old — is a screening candidate.
A negative stool exam has never ruled this out. That's not a hedge — it's the published sensitivity.
| Test | Sensitivity | Note |
|---|---|---|
| Single stool O&P (direct/concentration) | ~30–48% | Larval shedding is intermittent and low-volume even in true infection |
| Three serial stool exams | ~50% | Better, still misses roughly half of true infections |
| Agar plate culture / Baermann technique | 72–89% | Best of the fecal methods, but not widely available outside reference labs |
| Serum IgG serology (ELISA) | ~90–100% in immunocompetent hosts | Test of choice; one head-to-head study found 100% sensitivity vs. 45% for stool microscopy in travelers/migrants |
The catch: serology sensitivity drops in the exact patients you're most worried about — those already immunosuppressed, and those with acute/early infection — because the assay depends on the host still mounting an antibody response. False negatives are described specifically in immunosuppressed patients and false positives can occur from cross-reactivity with other helminths.primary source checked This is why serology plus stool exam (not either alone) is the recommended combined screening approach where time allows, and why eosinophilia is a supportive clue but never a rule-out on its own.
Same-day serology exists in very few hospitals. Emergencies don't wait for send-out labs.
Any plausible exposure history (Section 03) plus an indication for urgent, unavoidable immunosuppression — emergent transplant, status asthmaticus, antenatal steroids for imminent delivery, severe COVID-19 pneumonia on high-dose steroids.
If same-day testing isn't available and immunosuppression can't be safely delayed, guidance supports empiric treatment rather than withholding it pending results.
In patients with Central/West African residence history, screen for concurrent Loa loa microfilaremia (daytime blood smear) before ivermectin — high-burden loiasis plus ivermectin carries a risk of severe encephalopathy. This is the one hard contraindication-adjacent caveat to empiric dosing.
Single dose or two consecutive daily doses — CDC and most current protocols now favor the single-dose regimen (efficacy comparable, ~95%+ effectiveness in recent series). Relative contraindications: weight <15 kg, pregnancy/breastfeeding (weigh risk of untreated hyperinfection against treatment risk case-by-case), Loa loa co-infection per Step 3.
Falling eosinophil count and declining serology titer over follow-up support cure; repeat stool/serology at 1–2 years is the guideline-level recommendation given how easily low-level persistence hides.
You know the one.
Ivermectin spent 2020–2022 as a flashpoint: promoted online as a COVID-19 treatment despite no credible evidence of benefit against the virus itself, then formally recommended against for that indication by the FDA, CDC, and WHO. That controversy did real damage to the drug's reputation among both clinicians and the public — to the point that some hospital pharmacies reported supply pressure from inappropriate outpatient demand during the same period a legitimate, high-value use was quietly expanding.
During that same window, several hospitals implemented protocols to empirically dose ivermectin in COVID-19 patients about to receive high-dose corticosteroids — not to treat COVID, but to prevent exactly the hyperinfection syndrome described above in patients with unrecognized strongyloidiasis. That is the actual evidence-based use: a decades-old, WHO-essential-medicine-listed antiparasitic, dosed for a well-characterized parasitic disease, with a strong mechanistic and observational rationale. The drug never stopped being reasonable; the discourse just made it hard to say so out loud.primary source checked
The mechanism isn't controversial. The operational policy around it still is.
Ask the exposure question before you push the steroid dose. It costs thirty seconds. The alternative costs a patient a disease you had every chance to prevent.
[PRIMARY — CHECKED] Czeresnia JM, Weiss LM. Strongyloides stercoralis. Lung. 2022;200(2):141–148. PMID 35396957 — review confirming autoinfection biology, screening/empiric-treatment guidance, ivermectin dosing (200 mcg/kg × 1–2 days).
[PRIMARY — CHECKED] Strongyloides hyperinfection syndrome due to corticosteroid therapy after resection of meningioma. J Neurosurg Case Lessons. 2022. PMC9274291 — 70–100% mortality range, screening recommendation for endemic-exposure patients before immunosuppression.
[PRIMARY — CHECKED] Strongyloides Hyperinfection Syndrome Triggered by a Single Dose of Dexamethasone. Cureus/PMC10607639, and PMC10503402 (obstetric case) — single-dose corticosteroid trigger, ~90% untreated mortality.
[PRIMARY — CHECKED] Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries. PMC5590585 — stool method sensitivities (21–89% by technique), serology as most sensitive modality, false-negative risk in immunosuppressed hosts.
[PRIMARY — CHECKED] Clinical value of serology for diagnosis of strongyloidiasis in travelers/migrants (Bordier IVD ELISA study). PMC8647686 — serology 100% sensitivity vs. 45% stool microscopy; PPV 67%.
[PRIMARY — CHECKED] Modeling strongyloidiasis risk in the United States. Int J Infect Dis, 2020 — Appalachia/Southeastern U.S. endemicity, historical 3.8–20% prevalence data.
[PRIMARY — CHECKED] Evidence of Autochthonous Human S. stercoralis in South Carolina. Am J Trop Med Hyg, 2025 — 5.0% serosurvey seropositivity.
[PRIMARY — CHECKED] Strongyloides screening for heart transplant candidates in an endemic region (Kentucky). 2026 — 9.5% seropositivity, Appalachian residence association.
[PRIMARY — CHECKED] CDC. Presumptive Treatment and Screening for Strongyloidiasis (Refugee Health guidance); CDC Overseas Presumptive Treatment guidance — 200 mcg/kg ivermectin dosing, test-and-treat framework.
[PRIMARY — CHECKED] Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for High-Dose Corticosteroids in Severe COVID-19. Am J Trop Med Hyg, 2023 — empiric protocol rationale and precedent.
[PRIMARY — CHECKED] Ivermectin Effect on In-Hospital Mortality... Propensity-Matched Study. PMC10222278 — negative result for unselected empiric dosing, supporting risk-stratification argument.
[STANDARD TEACHING] WHO/World Gastroenterology Organisation strongyloidiasis management guidance — presumptive treatment framework, follow-up serology interval.
[UNVERIFIED IN TIME AVAILABLE] The remaining PMIDs listed in the original carousel's source comment (Buonfrate, Keiser, Inagaki, Kalantari, Sears, Swart, Barrett) were not individually re-pulled and checked against this document's specific claims; one (Czeresnia, 35396957) was independently confirmed above. Treat the others as the original author's citation list, not independently re-verified here.